Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk shareholders approve new board chair
Novo Nordisk's shareholders have approved Lars Rebien Sorensen as the company's new chairman in an extraordinary shareholder meeting, the company said on Friday.
Novo: The Double Bottom Is In
Novo Nordisk remains a compelling long-term healthcare compounder, despite mixed Q3 results and recent stock weakness. NVO's growth is driven by global obesity drug demand, robust pipeline development, and manufacturing scale, with Wegovy's international uptake and oral pill potential as key catalysts. Valuation is attractive with limited downside, fair sector-relative pricing, and technical signals suggesting a double bottom and bullish momentum.
Novo Nordisk: Long-Term Brand Dominance At A Bargain
Dominant mega-caps with low debt deserve investors' attention. In times of prosperity, waste is common—and often sets the stage for strong cash generation when the cycle turns. Novo is enacted solid counter-measures: the CVS deal, the crackdown on compounders, and aggressive cost cutting.
Novo Nordisk: Reliable Weigh-Loss Growth Story With More Upside Than Bears Admit
Novo Nordisk is significantly undervalued after a 20% stock price decline, now trading at a forward P/E of 13. NVO maintains strong growth prospects, driven by obesity treatment market expansion, international rollout, and cardiovascular label extensions. Recent drug-pricing agreements have reduced uncertainty, and most risks appear priced in, supporting a bullish long-term outlook for NVO.
This biotech is halting its work with Novo Nordisk and laying off more people
Korro is the latest to rethink its ties with the Danish pharma company.
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Exclusive: Novo Nordisk cuts Wegovy price by up to 33% in India, document shows
Danish drugmaker Novo Nordisk on Tuesday cut the price of its blockbuster weight-loss drug, Wegovy, by up to 33% in India, according to a document seen by Reuters.
Novo Nordisk: Buy This Bargain
Novo Nordisk A/S shares have declined sharply, but the company remains profitable with a positive long-term growth outlook and a strong cash position. NVO's decision to walk away from the Metsera, Inc. acquisition demonstrates disciplined capital allocation, with potential for organic growth, smaller deals, and shareholder returns. Despite slower growth due to competition and a maturing obesity drug market, NVO still posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk's extraordinary shareholders' meeting scheduled for November 14.
Novo Nordisk to sell weight loss drug Poviztra in India
Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on Monday.
Novo Nordisk: Hold On Tightly As The Market Tests Your Faith
Novo Nordisk faces persistent investor skepticism due to competitive pressures from Eli Lilly and repeated downward guidance revisions. NVO's recent management changes and strategic revamp aim to restore credibility, but execution risks remain high amid stalled growth and market share losses. Despite losing a bidding war to Pfizer, NVO's capital discipline and strong profitability position it well for future opportunities, including the upcoming oral Wegovy launch.
